As global markets experience fluctuations and economic indicators remain mixed, Hong Kong's tech sector continues to capture investor interest. In this dynamic environment, identifying high-growth stocks involves looking for companies with strong fundamentals, innovative technologies, and the ability to adapt to market changes.

Top 10 High Growth Tech Companies In Hong Kong

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs for unmet medical needs in China and internationally, with a market cap of HK$40.76 billion.

Operations: Kelun-Biotech generates revenue primarily from its pharmaceuticals segment, which reported CN¥1.88 billion. The company focuses on developing and commercializing novel drugs to meet unmet medical needs both in China and internationally.

Sichuan Kelun-Biotech Biopharmaceutical has demonstrated significant growth, with revenue increasing by 24.7% over the past year and earnings forecasted to grow at an annual rate of 8.53%. The company is heavily investing in R&D, which accounted for ¥1.38 billion in expenses last year, focusing on innovative treatments such as sacituzumab tirumotecan (sac-TMT) for various cancers. Recent clinical trials have shown promising results, such as a median progression-free survival of 5.6 months versus 2.7 months for sac-TMT compared to standard treatments in patients with TNBC. The biotech firm’s strategic focus on targeted therapies is evident from its ongoing Phase 3 studies and recent NDA submissions based on positive clinical outcomes. This approach not only positions them well within the high-growth tech landscape but also highlights their commitment to addressing unmet medical needs through advanced biopharmaceutical solutions. With a robust pipeline and strong financial performance, Kelun-Biotech is poised for continued innovation and potential market expansion in the coming years.

• Click here to discover the nuances of Sichuan Kelun-Biotech Biopharmaceutical with our detailed analytical health report.

• Learn about Sichuan Kelun-Biotech Biopharmaceutical's historical performance.

Tencent Holdings (SEHK:700)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tencent Holdings Limited, an investment holding company, provides value-added services (VAS), online advertising, fintech, and business services in China and internationally with a market cap of HK$3.45 trillion.

Operations: The company's primary revenue streams include Value-Added Services (VAS) at CN¥302.28 billion, Fintech and Business Services at CN¥209.17 billion, and Online Advertising at CN¥111.89 billion. The gross profit margin is a notable metric to consider for evaluating financial performance over time.

Tencent Holdings reported impressive Q2 2024 results, with revenue at ¥161.12 billion, up from ¥149.21 billion a year ago, and net income soaring to ¥47.63 billion from ¥26.17 billion. The company’s R&D expenses reflect its commitment to innovation, accounting for 8.2% of revenue in the last quarter, supporting advancements in AI and cloud services that drive future growth prospects. Tencent's earnings are forecasted to grow at an annual rate of 12.8%, outpacing the Hong Kong market's average growth rate of 11.7%.

• Delve into the full analysis health report here for a deeper understanding of Tencent Holdings.

• Explore historical data to track Tencent Holdings' performance over time in our Past section.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that researches, develops, manufactures, and commercializes antibody drugs with a market cap of approximately HK$53.38 billion.

Operations: Akeso focuses on the research, development, production, and sale of biopharmaceutical products, generating CN¥1.87 billion in revenue from these activities. The company specializes in antibody drugs within the biopharmaceutical sector.

Akeso's revenue is projected to grow at an impressive 33.1% annually, significantly outpacing the Hong Kong market's average of 7.3%. Despite a net loss of ¥238.59 million for H1 2024, the company's aggressive R&D investment underscores its commitment to innovation, with expenses accounting for a substantial portion of its budget. Recent advancements in their PD-1/VEGF bispecific antibody ivonescimab highlight Akeso's strategic focus on pioneering cancer treatments, potentially transforming therapeutic standards and driving future growth prospects.

• Unlock comprehensive insights into our analysis of Akeso stock in this health report.

• Understand Akeso's track record by examining our Past report.

Taking Advantage

• Click here to access our complete index of 45 SEHK High Growth Tech and AI Stocks.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com